Tonix Pharmaceuticals Receives FDA Alignment for TNX-4800 Phase 2 Trial
BERKELEY HEIGHTS, N.J., Aug. 3, 2026 Tonix Pharmaceuticals Holding Corp. announced that it has received official Type C meeting...
Tonix Pharmaceuticals
Advertisement
Tonix Publishes Mpox Study Supporting TNX-801 Vaccine
BERKELEY HEIGHTS, N.J., July 15, 2026 Tonix Pharmaceuticals announced the publication of new preclinical research in the Journal of...
Tonix Pharmaceuticals Secures Major Medicare Coverage Agreement for TONMYA
BERKELEY HEIGHTS, N.J., July 13, 2026 Tonix Pharmaceuticals announced a major managed Medicare payer agreement that will expand pharmacy...
Tonix Highlights Real-World Opioid Burden in Fibromyalgia at ASCP 2026
BERKELEY HEIGHTS, N.J., May 28, 2026 Tonix Pharmaceuticals presented new real-world data at the 2026 American Society of Clinical...
Tonix Wins FDA IND Clearance to Launch Phase 2 Depression Trial
Chatham, N.J. — Nov. 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
FDA Clears Tonix IND for TNX-102 SL in Major Depression
Chatham, New Jersey, November 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food & Drug Administration has cleared...
Tonix, MGH Collaborate on Phase 2 Trial of TNX-1500 to Prevent Kidney Transplant Rejection
CHATHAM, N.J., November 4, 2025: Tonix Pharmaceuticals Holding Corp. has announced a strategic collaboration with Massachusetts General Hospital (MGH)...
Advertisement
